Tropomyosin in mugwort cross-reacts to house dust mite, eliciting non-Th2 response in allergic rhinitis patients sensitized to house dust mite

• Research
• Open Access
• 
  

• Su Duan, 
• Limin Zhao, 
• Yuling Zhang, 
• Nan Zhang, 
• Ming Zheng, 
• Qiqi Wang, 
• Xu Zhang, 
• Xiangdong Wang, 
• Sun Ying, 
• Claus Bachert, 
• Luo Zhang & 
• Feng Lan 

Clinical and Molecular Allergy volume 19, Article number: 2 (2021) 

• details

Abstract

Background

Mugwort and house dust mite (HDM) are two of the most common inhalant allergens in Asia, however, whether mugwort affects polysensitized HDM+ allergic rhinitis (AR) patients has not been elucidated.

Methods

Overall, 15,884 AR outpatients were assessed for clinical status. Amino acid sequences of mugwort were determined by mass spectrometry. Afterward, cross-reactivity between mugwort tropomyosin and Dermatophagoides pteronyssinus 10 (Der p10) was analysed by ELISA inhibition and basophil activation experiments. To compare immunologic responses eliciting by two different tropomyosins, peripheral blood mononuclear cells (PBMCs) of HDM-monosensitized patients were stimulated by mugwort, HDM, Der p10 and synthetic peptides representing mugwort tropomyosin respectively.

Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)

• Research
• Open Access
• 
  

• Lubnaa Hossenbaccus, 
• Sophia Linton, 
• Jenny Thiele, 
• Lisa Steacy, 
• Terry Walker, 
• Crystal Malone & 
• Anne K. Ellis 

Allergy, Asthma & Clinical Immunology volume 17, Article number: 34 (2021) 

• details

Abstract

Rationale

The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility within the larger EEU.

Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

• Research article
• Open Access
• 
  

• Yassir A. Almofti, 
• Khoubieb Ali Abd-elrahman & 
• Elsideeq E. M. Eltilib 

BMC Immunology volume 22, Article number: 22 (2021) 

• details

Abstract

Background

The spread of a novel coronavirus termed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in China and other countries is of great concern worldwide with no effective vaccine. This study aimed to design a novel vaccine construct against SARS-CoV-2 from the spike S protein and orf1ab polyprotein using immunoinformatics tools. The vaccine was designed from conserved epitopes interacted against B and T lymphocytes by the combination of highly immunogenic epitopes with suitable adjuvant and linkers.

Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis

• Open Access

• Matsuo So, 
• Hiroki Kabata, 
• Koichi Fukunaga, 
• Hisato Takagi & 
• Toshiki Kuno 

BMC Pulmonary Medicine volume 21, Article number: 97 (2021) 

• details

Abstract

Background

The coronavirus disease 2019 (COVID-19) causes a wide spectrum of lung manifestations ranging from mild asymptomatic disease to severe respiratory failure. We aimed to clarify the characteristics of radiological and functional lung sequelae of COVID-19 patients described in follow-up period.

Practical challenges in oral immunotherapy resolved through patient-centered care

• Review
• Open Access

• 
  

• François Graham, 
• Douglas P. Mack & 
• Philippe Bégin 

volume details

Allergy, Asthma & Clinical Immunology 17, Article number: 31 (2021) 

Abstract

Oral immunotherapy (OIT) is now widely recognized as a valid option for the management of IgE-mediated food allergies. However, in real-life practice, OIT can lead to a variety of unique situations where the best course of action is undetermined. In patient-centered care, individual patient preferences, needs and values, should guide all clinical decisions. This can be achieved by using shared-decision making and treatment customization to navigate areas of uncertainty in a way that is responsive to patient’s needs and preferences.

The effect of Co-Q10 on allergic rhinitis and allergic asthma

• Research
• Open Access
• 
  

• Qixue Du, 
• Wei Meng, 
• Seyyed Shamsadin Athari & 
• Renzhong Wang 

Allergy, Asthma & Clinical Immunology volume 17, Article number: 32 (2021) 

• details

Abstract

Background

Allergic asthma is an inflammatory disease resulting from continued or intermittent allergen exposure, and allergic rhinitis can be trigger of asthma. The main mechanism of these disease is allergic reaction and immune response dysregulation. Co-Q10 is an enzyme cofactor in mitochondria can control asthma and allergic rhinitis symptoms. In the present study, we determined that the CoQ10-induced anti-allergic effects were mediated by up-regulation of Nrf2.

The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: a nested case control study

• Research
• Open Access
• 
  

• Sang Oh Kang, 
• Kyung Hyun Min, 
• Hyun Jeong Kim, 
• Tae Hyeok Kim, 
• Woorim Kim & 
• Kyung Eun Lee 

volume 

Asthma Research and Practice 7, Article number: 4 (2021)

Background

In March 2020, the US Food and Drug Administration decided that the dangers related to neuropsychiatric events (NPEs) of montelukast, one of the leukotriene modifying agents (LTMAs), should be communicated through ‘boxed warning’. In case of NPEs, the prevalence has been the highest in elderly people. Because the characteristics of the elderly such as old age itself can act as risk factors. Therefore, an investigation on safety of LTMAs related to NPEs in elderly using LTMAs is needed.

COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI)

• Guidelines
• Open Access
• 
  

• Timothy K. Vander Leek, 
• Edmond S. Chan, 
• Lori Connors, 
• Beata Derfalvi, 
• Anne K. Ellis, 
• Julia E. M. Upton & 
• Elissa M. Abrams 

Allergy, Asthma & Clinical Immunology volume 17, Article number: 29 (2021) 

• details

Abstract

Background

Safe and effective vaccines provide the first hope for mitigating the devastating health and economic impacts resulting from coronavirus disease 2019 (COVID-19) and related public health orders. Recent case reports of reactions to COVID-19 vaccines have raised questions about their safety for use in individuals with allergies and those who are immunocompromised. In this document, we aim to address these concerns and provide guidance for allergists/immunologists.